Clinical trials: CD - Crohn's Disease
Crohn Disease, Pediatric Crohns Disease
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
This is a multi-center, randomized, controlled open-label add-on design trial pilot study to evaluate the efficacy of personalized adjunctive antibiotic (azithromycin + metronidazole) therapy in pediatric subjects with mild to…
- Trial name
- PAZAZ (NCT04186247)
- Testing
- Azithromycin, Metronidazole, Standard of Care
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 13 people
- Sponsor
- University of North Carolina, Chapel Hill
Crohn's Disease
A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease
The study hypothesis is to establish the safety and tolerability of long-term open-label (OL) CP-690,550 therapy in subjects with Crohn's disease.
- Trial name
- NCT01470599
- Testing
- CP-690,550
- Where
- 75 sites in United States, Australia and 15 more
- Volunteers
- 150 people
- Sponsor
- Pfizer
Crohn's Disease
Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
The purpose of this study is to evaluate the clinical efficacy of D9421-C 9 mg once daily compared to Mesalazine 1 g three times a day to patients with mild to moderate active Crohn's disease affecting ileum, ileocecal region…
- Trial name
- NCT01514240
- Testing
- D9421-C capsule 3 mg, Mesalazine tablets
- Where
- 25 sites in Japan
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Inflammation, Crohn's Disease
The Effects of Naltrexone on Active Crohn's Disease
It is hypothesized that the opioid antagonist naltrexone will improve inflammation of the bowel and quality of life in subjects with active Crohn's disease compared to placebo.
- Trial name
- LDN (NCT00663117)
- Testing
- Naltrexone-HCl
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Milton S. Hershey Medical Center
Crohn's Disease
Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease
The primary objective of this study is to evaluate the efficacy of abrilumab as measured by the proportion of participants achieving Crohn's Disease Activity Index (CDAI) remission (CDAI < 150) after treatment for 8 weeks.
- Trial name
- NCT01696396
- Testing
- Abrilumab
- Where
- 84 sites in United States, Austria and 10 more
- Volunteers
- 254 people
- Sponsor
- Amgen
Crohn's Disease
Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
To determine the effect of a novel gut microbiota-targeted therapeutic regimen (bowel lavage and antibiotics with or without an antifungal) in the management of active Crohn's Disease (CD) that is refractory to conventional…
- Trial name
- Holiday (NCT02765256)
- Testing
- Fluconazole, Vancomycin, Neomycin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Pennsylvania
Crohn's Disease
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) as maintenance treatment in participants with moderately to severely active CD who achieved clinical response following administration…
- Trial name
- NCT02611817
- Testing
- Vedolizumab SC 108 mg, Vedolizumab IV 300 mg
- Where
- 194 sites in United States, Australia and 28 more
- Volunteers
- 644 people
- Sponsor
- Takeda
Axial Spondyloarthritis, Crohn Disease
MRE as a Screening Tool for axSpA in IBD
This study aims to assess the effectiveness (specificity and sensitivity) of using magnetic resonance enterography (MRE) as a screening tool for axial spondyloarthritis (axSpA) in patients with Crohns disease.
- Trial name
- ProSpA-CD (NCT03817983)
- Testing
- MRE review for evidence of axSpA in SIJs, Clinical assessment and dedicated MRI of the spine and pelvis
- Where
- United Kingdom
- Volunteers
- 259 people, healthy volunteers welcome
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Crohn's Disease, Ulcerative Colitis
Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease
Breastfeeding is beneficial to both mother and baby. However, many breastfeeding women are affected by long-term health conditions and need to take medications.
- Conditions
- Crohn's Disease, Ulcerative Colitis, Healthy Controls
- Trial name
- NCT03397108
- Testing
- The IBD group was divided into 2 subgroups: with or without anti-TNF antibody use
- Where
- 2 sites in Canada
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Fibrostenotic Crohn´s Disease
A Study to Test Whether Spesolimab Helps People With Crohn's Disease Who Have Symptoms of Bowel Obstruction
This study is open to adults, between 18 and 75 years of age, who have narrowings in the small bowel (strictures) due to Crohn's disease. Strictures can lead to bowel obstruction (blockage).
- Trial name
- NCT05013385
- Testing
- Spesolimab
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Crohn's Disease
Long-term Safety Study of Brodalumab in Adults With Crohn's Disease
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with brodalumab in adults with Crohn's disease.
- Trial name
- NCT01199302
- Testing
- Brodalumab
- Where
- 34 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Amgen
Colitis, Ulcerative, Crohn's Disease
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous (also known as Vedolizumab SC) in people with ulcerative colitis (UC) and Crohn's disease (CD).
- Trial name
- NCT02620046
- Testing
- Vedolizumab SC
- Where
- 301 sites in United States, Argentina and 31 more
- Volunteers
- 746 people
- Sponsor
- Takeda
Inflammatory Bowel Diseases, Ulcerative Colitis
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's Colitis
The primary aims of this phase I/II, randomized, placebo controlled study are the assessment of safety and tolerability of universal donor FMT compared to placebo in pediatric and young adult subjects (ages 5 years through 30…
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
- Trial name
- NCT02330653
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Stacy A. Kahn
Crohn's Disease, Inflammatory Bowel Disease
An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease
This study will assess the safety and tolerability of AIN457 in patients with moderate to severe Crohn's disease who already participated and completed the core trial CAIN457A2202.
- Trial name
- NCT01009281
- Testing
- AIN457
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease
This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled, parallel-group study to examine the efficacy, safety, and pharmacokinetics of vedolizumab (MLN0002) in induction and maintenance therapy in…
- Trial name
- NCT02038920
- Testing
- Vedolizumab
- Where
- 56 sites in Japan
- Volunteers
- 157 people
- Sponsor
- Takeda
Crohn's Disease
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
This study will assess the safety and efficacy of AIN457 in patients with moderate to severe active Crohn's disease.
- Trial name
- NCT00584740
- Testing
- AIN457
- Where
- 2 sites in Germany
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
The purpose of this study is to evaluate the safety of adalimumab for treatment of patients with moderate to severe Crohn's Disease (CD) and to measure the effects of treatment on patient general well-being, health-related…
- Trial name
- NCT00409617
- Testing
- adalimumab
- Where
- 189 sites in Austria, Belgium and 15 more
- Volunteers
- 945 people
- Sponsor
- Abbott
Ulcerative Colitis, Crohn's Disease
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease
The purpose of this multicenter, open-label study is to collect data on the occurrence of important clinical safety events resulting from chronic vedolizumab (MLN0002) administration.
- Trial name
- GEMINI LTS (NCT00790933)
- Testing
- Vedolizumab
- Where
- 41 sites in United States, Australia and 8 more
- Volunteers
- 2,243 people
- Sponsor
- Takeda
Crohn's Disease
Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease
To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol…
- Trial name
- NCT00195715
- Testing
- Adalimumab
- Where
- 111 sites in United States, Australia and 13 more
- Volunteers
- 777 people
- Sponsor
- Abbott
Crohn Disease
Crohn's Allogeneic Transplant Study
This phase II trial studies how well giving a donor bone marrow transplant (BMT) works in treating patients with refractory Crohn's Disease.
- Trial name
- CATS (NCT01570348)
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Fred Hutchinson Cancer Center